IMS MIDAS Market Segmentation - IMS Health

IMS MIDAS Market Segmentation
CLARITY AND CONFIDENCE IN A COMPLEX WORLD

IMS MIDAS Market
Segmentation is a new and
powerful global measurement
standard enabling rapid,
consistent definition of the
protected, unprotected and
generic pharmaceutical market:
Clearer identification of future
opportunities; development of
more effective product and
portfolio strategies and
delivery of continued growth.

IMS MIDAS Market Segmentation
Identify and quantify the full potential for future growth
with definitive information on generic, unprotected and
protected products using MIDAS Market Segmentation.
Authorised generics, patent protected brands, licensed early entries, copy products,
data exclusivity... the list goes on. Knowing where your true competition lies has
become a challenging but critical task in today’s increasingly complex markets.
IMS MIDAS Market Segmentation is the first of an extensive program of nextgeneration
market measurement services developed by IMS – New Models,
New Metrics – information-centred initiatives which are transforming our
foundation data assets: adding greater breadth and depth and creating new measures.
Bringing clarity and confidence in a complex world.
Private Label
Generics
Brands with
Pediatric
Exclusivity
Branded
Generics
CopyProducts
Unbranded
Generics
Generics with
Exclusivity
Authorized
Generics
Off-Patent
Brands
Protected
Market
Unprotected
Market
Generics
Market
POWERFUL INSIGHTS INTO MARKET COMPOSITION
Grounded in robust methodology, powerful analytics, and
the best global healthcare information, MIDAS Market
Segmentation provides a new way to understand and
measure the fundamental composition of the
pharmaceutical market.
At the heart of MIDAS Market Segmentation lies a unique
approach to coding products consistently across multiple
markets - for the first time allowing product performance
to be compared in an equivalent segment based on
protection status.
Using standard definitions developed with respected
industry associations, leading international companies and
the European Generic medicines Association (EGA),
MIDAS Market Segmentation enables:
• Clearer assessment of market opportunities
• An understanding of market position versus the
competition
• Consistent performance benchmarking
• Evaluation of late lifecycle options
• Market entry opportunities for successful generic
launches

Unique, total market visibility
TOTAL PRESCRIPTION-BOUND MARKET
Originally Protected
Never Protected
Protected
Not Protected
Never
Protected Generics
Other (copy) Products
INN Unbranded
Company Branded
Branded
THE UNPROTECTED MARKET
STEER YOUR PORTFOLIO TOWARDS THE BEST
OPPORTUNITIES
Lifecycle management is no longer an art but a proven
science that is essential to ensuring optimal ROI.
MIDAS Market Segmentation is a vital tool for confident
decision-making and portfolio planning to drive the
development of compelling lifecycle strategies, defend market
share, identify opportunities, and maintain competitive edge:
• Track movements and trends on a monthly basis
• More accurately model scenarios around protection
expiry, portfolio mix and company benchmarking
• Determine the opportunities and drivers for each
individual market segment
• Support your strategic direction with external stakeholders
• Ensure deployment of resources for the best results
TAKE FULL ADVANTAGE OF GENERICS POTENTIAL
The unprotected segment of the pharmaceutical market,
consisting of off-patent brands and generics, is commanding
increasing attention as the generics sector continues to
outperform overall market growth.
• Reliably identify your true competition including
unbranded, branded, and company branded generics plus
the original off-patent brand
• Consistently measure generics markets across geographies
• Identify the most attractive new markets for your future
generics portfolio
• Achieve the right portfolio mix
• Develop successful market entry strategies
FRESH INSIGHTS FOR A CHANGING WORLD
Establish market exclusivity expiry dates
• Explore the vulnerability of a corporation/therapy
class/molecule within future unprotected markets
Differentiate between protected and unprotected markets
• Identify the value of the protected/unprotected
market in a particular area
• Understand company brand strategy
in chosen markets
Assess the true market impact of generics on markets
• Evaluate time to peak generic penetration following
protection expiry
• Review strategies that have successfully limited
generic erosion in similar markets
Create powerful models for future launches
• Establish market and country differences in generic
launch strategies
• Compare sales or launch curves of subsequently
launched products with first launched products
• Understand lost sales from original brands
after protection expiry
• Determine optimum launch strategies
for an unprotected market
Develop new strategies for late lifecycle planning
• See how a line extension can protect the original brand
• Establish optimal launch time for a line extension
to protect an impending expiry

INTELLIGENCE. APPLIED.

ABOUT IMS
Operating in more than 100 countries, IMS
Health is the world's leading provider of market
intelligence to the pharmaceutical and healthcare
industries.With $1.8 billion in 2005 revenue and
more than 50 years of industry experience, IMS
offers leading-edge business intelligence products
and services that are integral to clients’ day-to-day
operations, including portfolio optimization
capabilities; launch and brand management
solutions; sales force effectiveness innovations;
managed care and over-the-counter offerings; and
consulting and services solutions that improve
ROI and the delivery of quality healthcare
worldwide. Additional information is available at
http://www.imshealth.com
IMS HEALTH®
EUROPE & WORLDWIDE
7 Harewood Avenue
London
NW1 6JB UK
Tel: +44 (0)20 3075 5888
Fax: +44 (0)20 3075 5999
THE AMERICAS
660 West Germantown Pike
Plymouth Meeting
PA 19462-0905
USA
Tel: +1 610 834 5206
Fax: +1 610 832 5438
www.imshealth.com/newmodelsnewmetrics
TM
©2006 IMS Health Incorporated or its affiliates. All Rights Reserved.
MSFO1006